SecBot SecBot
SECBOTREPLAY Home › Report › KYMR

KYMR · Elena Ridloff, a director at Kymera Therapeutics, filed a Form 144 to…

Kymera Therapeutics, Inc. · 144 filed Apr 1, 2026 at 16:42 ET

At the news

NEUTRALIMPACT 3/10

144 filed Apr 1, 2026 at 16:42 ET

Elena Ridloff, a director at Kymera Therapeutics, filed a Form 144 to sell up to 4,600 shares, following the exercise of stock options. This sale is part of a pre-arranged 10b5-1 trading plan and follows recent insider selling activity totaling $3.8M in the past 30 days.

  • Elena Ridloff, director of Kymera Therapeutics, filed Form 144 to sell up to 4,600 shares.
  • The shares were acquired through the exercise of stock options on March 31, 2026, and the sale is planned for April 1, 2026.
  • This is part of a pre-arranged 10b5-1 plan, indicating non-discretionary timing.
  • Ridloff has already sold 7,400 shares on March 31, 2026, for approximately $631,739.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access